CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results

April 16, 2026 - 02:06

CareDx, Inc., a precision medicine leader in transplant care, has entered a definitive agreement to sell its Lab Products business to EuroBio Scientific. The all-cash transaction is valued at $170 million and has received approval from the boards of directors of both companies.

This strategic divestiture allows CareDx to sharpen its focus on its core mission as "The Transplant Company." The move is designed to streamline operations and allocate resources toward advancing its suite of high-value diagnostic and digital solutions specifically for transplant patients and their caregivers. The company believes this increased focus will accelerate innovation and growth in its primary market.

Concurrently, CareDx provided preliminary financial results for the first quarter of 2026. The company expects total revenue to be approximately $72 million. Furthermore, CareDx anticipates reporting a positive cash flow from operations for the quarter, signaling a strengthening financial position as it executes its refined corporate strategy.

The transaction with EuroBio Scientific, a key player in the in vitro diagnostics field, is anticipated to close in the third quarter of 2026, pending customary regulatory approvals and closing conditions. The deal marks a significant strategic shift for CareDx as it doubles down on its commitment to the transplant community through precision medicine.